PT  - JOURNAL ARTICLE
AU  - Daniel E. Kaufman
AU  - Amy L. Kennalley
AU  - Kenneth L McCall
AU  - Brian J. Piper
TI  - Methadone overdoses increased 48% during the COVID-19 epidemic
AID  - 10.1101/2022.04.14.22273870
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.14.22273870
4099  - http://medrxiv.org/content/early/2022/04/19/2022.04.14.22273870.short
4100  - http://medrxiv.org/content/early/2022/04/19/2022.04.14.22273870.full
AB  - Background The United States (US) is in the middle of an opioid overdose epidemic that has spanned over two decades and continues to escalate. Methadone is long-acting full opioid agonist which has been approved to treat opioid use disorder (OUD). Methadone can cause respiratory depression that may result in mortality. The restrictions on methadone availability including take-home dosing were loosened during the COVID-19 pandemic although there have been concerns about the high street value of diverted methadone. This report examined how fatal overdoses involving methadone have changed over the past two-decades including during the pandemic.Methods The Center for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic Research (WONDER) database, which draws data from death certificates, was used to find the unintentional methadone related overdose death rate from 1999-2020. Unintentional methadone deaths were defined using the International Statistical Classification of Diseases (ICD), 10th revision codes: X40-44 with only data which was coded for methadone (T40.3). Data from the Automation of Reports and Consolidated Orders System (ARCOS) on methadone overall use, narcotic treatment programs use, and pain management use was gathered for all states, including the District of Columbia, for 2020 and corrected for population.Results There have been dynamic changes over the past two-decades in overdoses involving methadone. Overdoses increased from 1999 (0.9/million) to 2007 (15.9) and declined until 2019 (6.5). Overdoses in 2020 (9.6) were 48.1% higher than in 2019 (t(50) = 3.05, p < .005).The correlations between overall methadone use (r(49) = +0.75, p < 0.001), and narcotic treatment program use (r(49) = +0.77, p < 0.001) were positive, strong, and statistically significant. However, methadone use for pain treatment was not associated with overdoses (r(49) = -.08, p = .57).Conclusions Overdoses involving methadone significantly increased by 48.1% in 2020 relative to 2019. This mortality increase is much larger than the 5.3% elevation in calls involving methadone reported to poison control centers in the year following the March 16, 2020 loosening of methadone take-home regulations. Policy changes that were implemented following the COVID-19 pandemic involving methadone may warrant reconsideration.Competing Interest StatementBJP was part of an osteoarthritis research team supported by Pfizer and Eli Lilly from 2019-2021. The other authors have no relevant disclosures.Funding StatementThis study did not receive any external funding. BJP is supported by the Health Resources Services Administration (D34HP31025). The National Institute of Environmental Health Sciences (T32 ES007060‐31A1) provided software used for figure construction.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved as exempt by the Institutional Review Boards of the University of New England and Geisinger.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data for overdoses may be found at: https://wonder.cdc.gov/ Raw data for methadone distribution may be found at: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/ https://wonder.cdc.gov/ https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/